Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
RZLT Rezolute Inc
- Stocks
- Healthcare
- NASDAQ: RZLT
Price (delayed)
$4.25
Market cap
$363.46M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.15
Enterprise value
$350.64M
Rezolute is advancing targeted therapies for rare, metabolic, and life-threatening diseases. Its lead clinical asset, RZ358, is in Phase 2b development as a potential treatment for CHI, a rare pediatric
Highlights
RZLT's debt is down by 25% year-on-year and by 8% since the previous quarter
Rezolute's EPS has increased by 6% QoQ
Rezolute's equity has decreased by 17% QoQ but it has increased by 17% YoY
Rezolute's quick ratio has decreased by 28% YoY and by 9% from the previous quarter
Rezolute's net income has decreased by 25% YoY and by 2.6% from the previous quarter
Key stats
What are the main financial stats of RZLT
Market
Valuations
Earnings
Shares outstanding
85.52M
Market cap
$363.46M
Enterprise value
$350.64M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.12
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$77.15M
Net income
-$73M
EBIT
-$73M
EBITDA
-$72.45M
Free cash flow
-$65.6M
Per share
Balance sheet
Liquidity
EPS
-$1.15
EPS diluted
-$1.15
Free cash flow per share
-$0.94
Book value per share
$1.36
Revenue per share
$0
TBVPS
$1.35
Total assets
$94.74M
Total liabilities
$12.17M
Debt
$1.78M
Equity
$82.57M
Working capital
$78.21M
Debt to equity
0.02
Current ratio
8.43
Quick ratio
8.25
Net debt/EBITDA
0.18
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-63.1%
Return on equity
-70.1%
Return on invested capital
-89.1%
Return on capital employed
-86.7%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RZLT stock price
How has the Rezolute stock price performed over time
Intraday
-3.85%
1 week
7.59%
1 month
6.25%
1 year
-8.6%
YTD
-13.27%
QTD
46.55%
Financial performance
How have Rezolute's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$77.15M
Net income
-$73M
Gross margin
N/A
Net margin
N/A
Rezolute's operating income has decreased by 25% YoY and by 5% from the previous quarter
Rezolute's net income has decreased by 25% YoY and by 2.6% from the previous quarter
Price vs fundamentals
How does RZLT's price correlate with its fundamentals
Growth
What is Rezolute's growth rate over time
Valuation
What is Rezolute stock price valuation
P/E
N/A
P/B
3.12
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Rezolute's EPS has increased by 6% QoQ
The stock's price to book (P/B) is 95% more than its 5-year quarterly average of 1.6 and 42% more than its last 4 quarters average of 2.2
Rezolute's equity has decreased by 17% QoQ but it has increased by 17% YoY
Efficiency
How efficient is Rezolute business performance
The company's return on invested capital fell by 40% YoY and by 4.5% QoQ
RZLT's return on assets is down by 16% year-on-year
The ROE is down by 15% year-on-year
Dividends
What is RZLT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RZLT.
Financial health
How did Rezolute financials performed over time
Rezolute's current ratio has decreased by 29% YoY and by 9% from the previous quarter
Rezolute's quick ratio has decreased by 28% YoY and by 9% from the previous quarter
RZLT's debt is 98% smaller than its equity
RZLT's debt to equity is down by 33% year-on-year
RZLT's debt is down by 25% year-on-year and by 8% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.